dr rini on the background of a biomarker analysis of keynote-426 in rcc
Published 4 months ago • 21 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:18
dr rini on a biomarker analysis of keynote-426 using subtype clustering rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
9:05
drs. rini, wallis on a 5-year analysis of keynote-426 for advanced clear cell rcc
-
6:58
keynote-426 study
-
1:33
dr. rini on challenges with biomarkers in rcc
-
0:49
dr. rini describes hypertension as a biomarker in rcc
-
0:53
dr. rini on standards of care for advanced rcc
-
1:33
biomarker analysis of the clear & keynote-426 trials in arcc
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
26:06
kidney cancer | dr. tony talebi discusses the treatment of stage 4 metastatic renal cell carcinoma
-
2:44
how is immunotherapy used to fight cancer? | dana-farber cancer institute | science illustrated
-
8:15
drs. mckay, braun on current landscape and potentially actionable developments in biomarkers in rcc
-
5:18
pd-l1 expression as a biomarker in renal cell carcinoma
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
5:57
pbrm1 as a biomarker for renal cell carcinoma
-
1:57
dr. agarwal discusses results of keynote-426 in mrcc
-
3:08
evaluation of axitinib use as a neoadjuvant in rcc
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma
-
0:38
dr. rini explains the axitinib integration process
-
1:02
dr. uzzo on biomarker development for rcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:12
dr. rini describes axitinib's and sorafenib's side effects